Previous 10 | Next 10 |
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 New patent issued by USPTO for use of Gencaro in treating atrial fibrillation in heart failure patients with ejection fractions gr...
Penny Stocks Continue Captivating The Market If you look at the top 10 most active stocks in the market today by volume, more than half were penny stocks . This has remained a key theme in January, with new traders flocking to cheap stocks. Are they worth the time? Well, apparently ...
Will These Biotech Penny Stocks Continue to See Adoration From Investors? Biotech penny stocks have become some of the most popular investments throughout the pandemic. Prior to this, biotech stocks were also quite popular, but not to the extent that they are now in my opinion. With...
The first patients have been enrolled in ARCA biopharma's (ABIO) ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 (AB201) as a potential treatment for patients hospitalized with COVID-19.The first patient was enrolled at the University of Colorado Hospital on December 10, 20...
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccines rNAPc2 is the only novel compound being developed for COVID-19 Associated Coagulopathy Topline trial data anticipated in the second quarter of 2021 ...
WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00 a.m. MT, now will be held at the company’s offices located at 10170 Church Ra...
ARCA Biopharma (ABIO) jumped 5.5% in today's trade for its highest close in a month after saying it received Fast Track designation from the U.S. Food and Drug Administration for its AB201 experimental COVID-19 treatment.ARCA says it plans to start a Phase 2b clinical trial of AB201 next mont...
Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or not AB201 is the only novel compound being developed for COVID Associated Coagulopathy Initiation of ASPEN-COVID-19 Phase 2b clinical trial anticipated in December...
ARCA biopharma (ABIO): Q3 GAAP EPS of -$0.33.Cash and cash equivalents of $51.1M.Shares are up 0.5% PM.Press Release. For further details see: ARCA biopharma reports Q3 results
Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID 19 anticipated in fourth quarter Topline data from trial anticipated Q2 2021 WESTMINSTER, Colo., Nov. 02, 2020 (G...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / May 22, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sale...
ARCA biopharma and Oruka Therapeutics announce Merger Agreement ARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company app...